Australian Clinical Labs Ltd ( (AU:ACL) ) just unveiled an announcement.
Australian Clinical Labs Limited has announced an update regarding its ongoing share buy-back program. The company reported that it bought back 15,138 ordinary fully paid securities on the previous day, adding to a total of 3,249,987 securities repurchased to date. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Limited operates in the healthcare industry, focusing on providing pathology services. The company is known for its diagnostic testing services and caters to a wide range of healthcare needs across Australia.
YTD Price Performance: -11.76%
Average Trading Volume: 857,265
Technical Sentiment Signal: Buy
Current Market Cap: A$592.3M
See more insights into ACL stock on TipRanks’ Stock Analysis page.